REGULATION OF MEMORY B CELL RESPONSES TO POLYSACCHARIDE ANTIGENS
REGULATION OF MEMORY B CELL RESPONSES TO POLYSACCHARIDE ANTIGENS
批准号:
8820783
负责人:
Karen M Haas
金额:
$25.9万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-10 至 2016-03-31
关键词:
AdjuvantAdultAgonistAntibodiesAntibody FormationAntibody-Producing CellsAntigensB Cell ProliferationB-LymphocytesBacteriaC Type Lectin ReceptorsCD28 geneCD80 geneCTLA4 geneCessation of lifeChildConjugate VaccinesDataDefectDiseaseEncapsulatedEnhancing AntibodiesFunctional disorderFutureGenerationsGoalsHealthImmune responseImmune systemImmunizationImmunosuppressionIn VitroInfectionKnowledgeLeadLifeLigandsMediatingMemoryMemory B-LymphocytePathway interactionsPattern recognition receptorPneumococcal InfectionsPneumococcal vaccinePneumovaxPolysaccharidesPolyvalent pneumococcal vaccineProblem SolvingProteinsPublic HealthPublishingReceptor SignalingRegulationRegulatory PathwayResearchRoleSecondary toSerotypingSignal TransductionStreptococcus pneumoniaeTLR4 geneTestingTrehaloseVaccinationVaccinesbasecell typecostdesignimprovedkillingsmembermonophosphoryl lipid Apathogenpreventreceptorresponsevaccine efficacy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Streptococcus pneumoniae kills more people in the U.S. than all other vaccine-preventable diseases combined and is estimated to cause over 1.6 million deaths/year worldwide. The native pneumococcal vaccine currently used in adults consists of capsular polysaccharides (PPS) derived from 23 different serotypes and therefore provides broad coverage against invasive disease. Nonetheless, protection eventually wanes as antibody titers diminish, typically by 10 years post-immunization. Unfortunately, PPS boosting does not induce recall responses. This is typical of most polysaccharide (Ps) antigens. This is a significant concern given the potential for diminished protection against pneumococcal infections. PPS-protein conjugate vaccines do not effectively boost or yield superior titers to native PPS in adults, in contrast to what is observed in young children. This, along with the high cost and limited serotype coverage of conjugate vaccines, suggests that alternative strategies are needed to enhance PPS vaccine efficacy. To improve native Ps vaccines, it is imperative to develop a mechanistic understanding of the factors preventing Ps-specific antibody recall responses. Our data supports that memory B cells are generated in response to Ps antigens but that they are largely unresponsive when antigen is re-encountered following infection or revaccination. Our data also suggest that select adjuvant combinations may overcome this defect and enable successful boosting. In this proposal, we will test the hypothesis that active mechanisms of immune suppression limit Ps-specific memory B cell generation and functional responsiveness to secondary antigen encounter. In addition, we will test the hypothesis that "danger" signals supplied through toll-like (TLR) and C-type lectin receptors (CLR) can overcome this suppression. In Aim 1, we will specifically examine the B cell-intrinsic and -extrinsic roles for B7:CD28 superfamily inhibitory receptors and ligands in suppressing Ps-specific memory B cell formation and effector function. In Aim 2, we will examine the extent to which TLR4/RP105 and Mincle agonists synergize to promote Ps-specific memory B cell generation and functional responsiveness during boosting. We will examine the mechanisms by which this is achieved, including the extent to which these agonists overcome the inhibitory effects of B7:CD28 superfamily receptors. Completion of these studies is expected to provide us with critical knowledge regarding the mechanisms responsible for suppressed secondary antibody responses to native Ps as well as the feasibility of using TLR and CLR-based adjuvant combinations to overcome this barrier to effective vaccination. Our results are expected to have a significant impact on the use of prime-boost strategies employing native Ps, as well as the future design of more affordable and efficacious Ps-based vaccines with the highest possible serotype coverage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of B cells in controlling Klebsiella pneumoniae associated disease states
-
批准号:10731411
-
项目类别:
-
资助金额:$19.38万
-
财政年份:2023
-
负责人:Karen M Haas
-
依托单位:
Leveraging B cell specificities for tumor glycans to elicit potent anti-tumor immunity
-
批准号:10502322
-
项目类别:
-
资助金额:$41.98万
-
财政年份:2022
-
负责人:Karen M Haas
-
依托单位:
THE IMPACT OF ADVANCED AGE AND SEX ON HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE
-
批准号:10532071
-
项目类别:
-
资助金额:$53.2万
-
财政年份:2022
-
负责人:Karen M Haas
-
依托单位:
Leveraging B cell specificities for tumor glycans to elicit potent anti-tumor immunity
-
批准号:10662537
-
项目类别:
-
资助金额:$41.39万
-
财政年份:2022
-
负责人:Karen M Haas
-
依托单位:
THE IMPACT OF ADVANCED AGE AND SEX ON HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE
-
批准号:10693951
-
项目类别:
-
资助金额:$53.34万
-
财政年份:2022
-
负责人:Karen M Haas
-
依托单位:
Viral Modulation of Polysaccharide Antibody Responses and Vaccine Efficacy
-
批准号:9018144
-
项目类别:
-
资助金额:$19.48万
-
财政年份:2016
-
负责人:Karen M Haas
-
依托单位:
Regulation of Memory B Cell Responses to Polysaccharide Antigens
-
批准号:8944119
-
项目类别:
-
资助金额:$38.44万
-
财政年份:2015
-
负责人:Karen M Haas
-
依托单位:
Regulation of Memory B Cell Responses to Polysaccharide Antigens
-
批准号:9266278
-
项目类别:
-
资助金额:$38.44万
-
财政年份:2015
-
负责人:Karen M Haas
-
依托单位:
Regulation of Memory B Cell Responses to Polysaccharide Antigens
-
批准号:9465418
-
项目类别:
-
资助金额:$38.44万
-
财政年份:2015
-
负责人:Karen M Haas
-
依托单位:
Regulation of Memory B Cell Responses to Polysaccharide Antigens
-
批准号:9056974
-
项目类别:
-
资助金额:$38.44万
-
财政年份:2015
-
负责人:Karen M Haas
-
依托单位:
REGULATION OF PROTECTIVE HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE BY PD-1
-
批准号:8263369
-
项目类别:
-
资助金额:$18.5万
-
财政年份:2011
-
负责人:Karen M Haas
-
依托单位:
REGULATION OF PROTECTIVE HUMORAL IMMUNITY TO STREPTOCOCCUS PNEUMONIAE BY PD-1
-
批准号:8173470
-
项目类别:
-
资助金额:$22.2万
-
财政年份:2011
-
负责人:Karen M Haas
-
依托单位:
海外基金